Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

  • C. Festuccia1Email author,
  • A. Mancini2,
  • A. Colapietro2,
  • G. L. Gravina2, 3,
  • F. Vitale4,
  • F. Marampon3,
  • S. Delle Monache5,
  • S. Pompili6,
  • L. Cristiano7,
  • A. Vetuschi6,
  • V. Tombolini8,
  • Y. Chen9 and
  • T. Mehrling10
Journal of Hematology & Oncology201811:38

https://doi.org/10.1186/s13045-018-0587-3

Received: 8 March 2018

Accepted: 8 March 2018

Published: 14 March 2018

The original article was published in Journal of Hematology & Oncology 2018 11:32

Erratum

The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales.
Figure 1
Fig. 4

Morphological and functional effects of TINO when combined with RT in glioma cell lines. a Morphological changes observed in U251 cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. b Morphological changes observed in U87MG cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. c Representative expression of acidic vacuolar organelle (AVO) accumulation in T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. d Percentage of AVO-stained cells in U87MG, U251, and T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. Statistical analysis: *p < 0.005 in the comparison between combined TINO + RT treatment and RT alone. Single results are representative of three different experiments performed in triplicate. e Immunocytochemical evaluation of γH2Ax stain in T98G cells cultured with 4, 6, and 8 Gy (RT) alone or in association with TINO 3.5 μM. f Quantization of γH2AX expression in U87MG, U251, and T98G cells treated with RT with or without TINO. Statistical analyses: *p < 0.005 in the comparison between RT + TINO and RT or TINO treatments alone. Single results are representative of three different experiments performed in triplicate

This has now been corrected, and can be seen ahead and in the original article [1].

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L’Aquila, L’Aquila, Italy
(2)
Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L’Aquila, L’Aquila, Italy
(3)
Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L’Aquila, L’Aquila, Italy
(4)
Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L’Aquila, L’Aquila, Italy
(5)
Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L’Aquila, L’Aquila, Italy
(6)
Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L’Aquila, L’Aquila, Italy
(7)
Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
(8)
Division of Radiotherapy, Department of Experimental Medicine, University of Rome “La Sapienza”, Rome, Italy
(9)
Northlake International LLC, Pleasanton, USA
(10)
Mundipharma-EDO GmbH, Basel, Switzerland

Reference

  1. Festuccia C, et al. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018;11:32.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement